is glp-3 retatrutide (RT) | Advanced Weight Loss Support GLP-3 (Retatrutide) Research Peptide For

Intervertebral Disc Degeneration GLP-1 protects nucleus pulposus cells (NPCs) ( the primary cell type driving disc integrity) by inhibiting AP-1driven catabolic gene transcription (specifically BATF/JUN heterodimers that drive MMP13 and ADAMTS5), curtailing NF-B via SIRT1 upregulation, and differentially modulating STAT3 (suppressing pathological senescence in NPCs while promoting M2 macrophage polarization)

The FLOW trial demonstrated meaningful reductions in kidney disease progression with semaglutide. The SELECT trial showed a 20% reduction in major adverse cardiovascular events in patients with obesity and established cardiovascular disease. These are not trivial findings

Nonetheless, the dose is typically not more than 2 mg once a week

Who is making that one

Whats Coming Next for GLP-1 and Metabolic Disease Treatment Moving from academia to industry led to advancing groundbreaking diabetes and obesity therapies

Colors indicate strength of LD